Chimeric antigen receptor (CAR) T-cell therapy is a novel therapy representing a paradigm shift in haematological malignancy treatment over the past decade; examples include the use of anti-CD19/22 CAR cocktail therapy to treat relapsed/refractory B-cell lymphoma [1] and anti-B-cell maturation antigen (BCMA) CAR therapy for relapsed/refractory multiple myeloma [2]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.